XML 48 R31.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Significant Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($) | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Jun. 30, 2010 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Mar. 31, 2018
Mitsubishi Tanabe |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Up-front license fees |  |  |  |  | $ 30,000,000 |
Collaborative agreement maximum additional payment to receive |  |  |  |  | 85,000,000 |
Patent rights period |  | The longer of ten years or the life of the related patent rights. |  |  |  |
Collaborative arrangement right description |  | Under the terms of the agreement, Mitsubishi Tanabe is responsible for all third-party development, marketing and commercialization costs in Japan and other select Asian markets and the Company would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties. There are no performance, cancellation, termination, or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days written notice to the Company. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to the Company. |  |  |  |
Collaboration termination notice period |  | 180 days |  |  |  |
Revenues recognized under collaboration agreement |  | $ 0 | $ 15,000,000 | $ 0 | 19,800,000 |
Deferred revenues under collaboration |  |  |  |  | $ 10,200,000 |
Mitsubishi Tanabe | Topic 606 |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Clinical trial cost |  | 12,000,000 |  |  |  |
Up-front consideration received |  | $ 30,000,000 |  |  |  |
AbbVie |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Up-front license fees | $ 75,000,000 |  |  |  |  |
Patent rights period |  | Ten years or the life of the related patent rights. |  |  |  |
Collaborative arrangement right description |  | The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. |  |  |  |
Collaboration termination notice period |  | 180 days |  |  |  |
Revenues recognized under collaboration agreement |  | $ 40,000,000 | 30,000,000 | $ 15,000,000 |  |
Sales-based royalties |  | 1,600,000 |  |  |  |
AbbVie | Development and Regulatory Milestone Payments |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Collaborative agreement maximum additional payment to receive |  | 480,000,000 |  |  |  |
Collaborative agreement payment received |  | 115,000,000 |  |  |  |
AbbVie | Commercial Milestone Payments |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Collaborative agreement maximum additional payment to receive |  | 50,000,000 |  |  |  |
AbbVie | Topic 606 |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Up-front consideration received |  | $ 75,000,000 |  |  |  |
B I A L |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Up-front license fees |  |  | $ (30,000,000) |  |  |
License agreement date |  |  | Feb. 09, 2017 |  |  |
B I A L | Event Based Milestones |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Milestone payables |  |  |  |  |  | $ 10,000,000
B I A L | Regulatory Approval and Net Sales Milestones |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Milestone payables |  |  |  |  |  | 105,000,000
B I A L | Regulatory and Clinical Results and FDA Acceptance Milestones |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems] |  |  |  |  |  |
Milestone payables |  |  |  |  |  | $ 10,000,000

X
- Definition The estimated cost of a clinical trial in the event that a clinical trial is requested by the collaborative party. + References No definition available. + Details
Name: | nbix_ClinicalTrialCosts
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone revenue, sponsored research and development, and amortization of up front licensing fees recognized during the period under a collaborative agreement with a third-party. + References No definition available. + Details
Name: | nbix_CollaborationRevenue
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of contingent consideration received as a result of satisfying a condition or requirement of a collaborative agreement. + References No definition available. + Details
Name: | nbix_CollaborativeArrangementContingentPaymentReceived
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The maximum amount of contingent payments received under collaborative arrangements. + References No definition available. + Details
Name: | nbix_CollaborativeArrangementMaximumContingentPaymentsAmount
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement upfront consideration received. + References No definition available. + Details
Name: | nbix_CollaborativeArrangementUpfrontConsiderationReceived
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Up front payments received (paid) under collaborative agreements for sponsored research and development, and licensing fees + References No definition available. + Details
Name: | nbix_CollaborativeArrangementUpfrontPaymentReceivedPaid
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period of time the company is entitled to a percentage of worldwide sales under the collaboration agreement. + References No definition available. + Details
Name: | nbix_ContractTerminationProvisionTerm
Namespace Prefix: | nbix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Date of the license agreement, in CCYY-MM-DD format. + References No definition available. + Details
Name: | nbix_LicenseAgreementDate
Namespace Prefix: | nbix_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of potential milestone payments to be paid under a license agreement. + References No definition available. + Details
Name: | nbix_PotentialMilestonePayments
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sales based royalties. + References No definition available. + Details
Name: | nbix_SalesBasedRoyalties
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of time required for third party collaborator to give written notice prior to terminating the collaborative agreement. + References No definition available. + Details
Name: | nbix_TerminationNoticePeriod
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of rights and obligations under the collaborative arrangements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_CollaborativeArrangementRightsAndObligations
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References No definition available. + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nbix_ClinicalDevelopmentAndRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nbix_CommercializationEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_EventBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_RegulatoryApprovalAndNetSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_RegulatoryApprovalClinicalResultsAndFdaAcceptanceMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |